يعرض 1 - 10 نتائج من 545 نتيجة بحث عن '"hyper-ige syndrome"', وقت الاستعلام: 1.07s تنقيح النتائج
  1. 1
    دورية أكاديمية
  2. 2
    دورية أكاديمية
  3. 3
    دورية أكاديمية
  4. 4
    دورية أكاديمية

    المؤلفون: ZHANG Yuqiao, ZENG Yueping

    المصدر: 罕见病研究, Vol 2, Iss 2, Pp 294-302 (2023)

    وصف الملف: electronic resource

  5. 5
    دورية أكاديمية
  6. 6
    دورية أكاديمية
  7. 7
    دورية أكاديمية
  8. 8
    دورية أكاديمية
  9. 9
    دورية أكاديمية
  10. 10
    دورية أكاديمية

    المصدر: Meditsinskiy sovet = Medical Council; № 2 (2023); 122-128 ; Медицинский Совет; № 2 (2023); 122-128 ; 2658-5790 ; 2079-701X

    وصف الملف: application/pdf

    العلاقة: https://www.med-sovet.pro/jour/article/view/7397/6598Test; Boguniewicz M., Leung D. Atopie Dermatitis. In: Jaffe H.S., Bucalo L.R., Sherwin S.A. (eds.). Anti-Infective Applications of Interferon-Gamma. Boca Raton: CRC Press; 1992, pp. 67–84. https://doi.org/10.1201/9781003066903Test.; Giavina-Bianchi M., Rizzo L.V., Giavina-Bianchi P. Severe atopic dermatitis: Dupilumab is not just safer, but more efficient. Allergol Immunopathol (Madr). 2020;48(6):792–797. https://doi.org/10.1016/j.aller.2019.12.005Test.; Silverberg J.I., Hanifin J.M. Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study. J Allergy Clin Immunol. 2013;132(5):1132–1138. https://doi.org/10.1016/j.jaci.2013.08.031Test.; Silverberg J.I., Barbarot S., Gadkari A., Simpson E.L., Weidinger S., Mina-Osorio P. et al. Atopic dermatitis in the pediatric population: A crosssectional, international epidemiologic study. Ann Allergy Asthma Immunol. 2021;126(4):417–428.e2. https://doi.org/10.1016/j.anai.2020.12.020Test.; Kawai K., Kawai K., Kamei N., Kishimoto S. Levels of serum IgE, serum soluble-Fc epsilon RII, and Fc epsilon RII(+) peripheral blood lymphocytes in atopic dermatitis. J Dermatol. 1992;19(5):285–292. https://doi.org/10.1111/j.1346-8138.1992.tb03226.xTest.; Laske N., Niggemann B. Does the severity of atopic dermatitis correlate with serum IgE levels? Pediatr Allergy Immunol. 2004;15(1):86–88. https://doi.org/10.1046/j.0905-6157.2003.00106.xTest.; Wollenberg A., Thomsen S.F., Lacour J.P., Jaumont X., Lazarewicz S. Targeting immunoglobulin E in atopic dermatitis: A review of the existing evidence. World Allergy Organ J. 2021;14(3):100519. https://doi.org/10.1016/j.waojou.2021.100519Test.; Tokura Y. Atopic Dermatitis: Common Extrinsic and Enigmatic Intrinsic Types. In: Kabashima K. (ed.). Immunology of the Skin. Tokyo: Springer; 2016, pp. 339–358. https://doi.org/10.1007/978-4-431-55855-2_21Test.; Holm J.G., Agner T., Clausen M.L., Thomsen S.F. Determinants of disease severity among patients with atopic dermatitis: association with components of the atopic march. Arch Dermatol Res. 2019;311(3):173–182. https://doi.org/10.1007/s00403-019-01895-zTest.; Pugliarello S., Cozzi A., Gisondi P., Girolomoni G. Phenotypes of atopic dermatitis. J Dtsch Dermatol Ges. 2011;9(1):12–20. https://doi.org/10.1111/j.1610-0387.2010.07508.xTest.; Lévy R., Béziat V., Barbieux C., Puel A., Bourrat E., Casanova J.L., Hovnanian A. Efficacy of Dupilumab for Controlling Severe Atopic Dermatitis in a Patient with Hyper-IgE Syndrome. J Clin Immunol. 2020;40(2):418–420. https://doi.org/10.1007/s10875-020-00751-4Test.; Su C.J., Tseng H.C. Treatment efficacy of dupilumab in a hyper-immunoglobulin E syndrome patient with severe atopic dermatitis. JAAD Case Rep. 2021;11:60–62. https://doi.org/10.1016/j.jdcr.2021.03.007Test.; Joshi T.P., Anvari S., Gupta M.R., Davis C.M., Hajjar J. Case Report: Dupilumab Successfully Controls Severe Eczema in a Child With Elevated IgE Levels and Recurrent Skin Infections. Front Pediatr. 2021;9:646997. https://doi.org/10.3389/fped.2021.646997Test.; Pelaia C., Pelaia G., Crimi C., Maglio A., Armentaro G., Calabrese C. et al. Biological Therapy of Severe Asthma with Dupilumab, a Dual Receptor Antagonist of Interleukins 4 and 13. Vaccines (Basel). 2022;10(6):974. https://doi.org/10.3390/vaccines10060974Test.; Hamilton J.D., Harel S., Swanson B.N., Brian W., Chen Z., Rice M.S. et al. Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases. Clin Exp Allergy. 2021;51(7):915–931. https://doi.org/10.1111/cea.13954Test.; Le Floc’h A., Allinne J., Nagashima K., Scott G., Birchard D., Asrat S. et al. Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Rα antibody, is required to broadly inhibit type 2 inflammation. Allergy. 2020;75(5):1188–1204. https://doi.org/10.1111/all.14151Test.; Paller A.S., Simpson E.L., Siegfried E.C., Cork M.J., Wollenberg A., Arkwright P.D. et al. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebocontrolled, phase 3 trial. Lancet. 2022;400(10356):908–919. https://doi.org/10.1016/S0140-6736Test(22)01539-2.; https://www.med-sovet.pro/jour/article/view/7397Test